Atlas Trials

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Clinical trial NCT05091567 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05091567
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Small-Cell Lung Cancer
Start date
2021-11-18
Primary completion
2024-07-29
Enrollment
660

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.